Merck Serono launches Kuvan in Europe
Merck Serono, a division of Germany's Merck KGaA, has launched Kuvan (sapropterin dihydrochloride) in Europe. The drug is indicated for hyperphenylalaninemia due to phenylketonuria or tetrahydrobiopte-rin deficiency, and is the only treatment available in Europe for HPA due to these two rare genetic diseases leading to an abnormally high concentration of phenylalanine in the blood. Beginning with France, Germany and the UK, Kuvan will be rolled out in a total of 13 European countries this year. "In the USA, where Kuvan has been available since 2007, we have received positive testimonials from health care professionals and from the patients whose quality of life has improved thanks to treatment with Kuvan," said Roberto Gradnik, executive vice president commercial Europe at Merck Serono.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze